MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - VENUS REMEDIES
ASTRAZENECA PHARMA vs VENUS REMEDIES - Comparison Results
Current Valuations
| ASTRAZENECA PHARMA | VENUS REMEDIES | ASTRAZENECA PHARMA/ VENUS REMEDIES |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 87.3 | -0.9 | - | View Chart |
| P/BV | x | 19.3 | 0.1 | 29,500.6% | View Chart |
| Dividend Yield | % | 0.0 | 0.0 | - |
Financials
 ASTRAZENECA PHARMA  VENUS REMEDIES |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
VENUS REMEDIES Mar-18 |
ASTRAZENECA PHARMA/ VENUS REMEDIES |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 126 | 1,015.1% | |
| Low | Rs | 883 | 61 | 1,444.5% | |
| Sales per share (Unadj.) | Rs | 228.4 | 301.8 | 75.7% | |
| Earnings per share (Unadj.) | Rs | 10.4 | -24.9 | -41.7% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 2.5 | 639.0% | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 98.8 | 293.3 | 33.7% | |
| Shares outstanding (eoy) | m | 25.00 | 12.34 | 202.6% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 0.3 | 1,526.7% | |
| Avg P/E ratio | x | 104.2 | -3.8 | -2,772.6% | |
| P/CF ratio (eoy) | x | 66.4 | 36.7 | 180.8% | |
| Price / Book Value ratio | x | 10.9 | 0.3 | 3,430.7% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 27,008 | 1,154 | 2,340.8% | |
| No. of employees | `000 | 1.4 | 0.9 | 146.6% | |
| Total wages/salary | Rs m | 1,535 | 393 | 390.6% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 4,026.1 | 104.6% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 425.0 | 266.4% | |
| Avg. net profit/employee | Rs Th | 191.1 | -331.8 | -57.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 3,724 | 153.3% | |
| Other income | Rs m | 123 | 23 | 544.4% | |
| Total revenues | Rs m | 5,833 | 3,747 | 155.7% | |
| Gross profit | Rs m | 463 | 395 | 117.2% | |
| Depreciation | Rs m | 147 | 338 | 43.6% | |
| Interest | Rs m | 0 | 354 | 0.0% | |
| Profit before tax | Rs m | 438 | -275 | -159.1% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 32 | 566.1% | |
| Profit after tax | Rs m | 259 | -307 | -84.4% | |
| Gross profit margin | % | 8.1 | 10.6 | 76.5% | |
| Effective tax rate | % | 40.8 | -11.5 | -355.8% | |
| Net profit margin | % | 4.5 | -8.2 | -55.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 2,638 | 121.7% | |
| Current liabilities | Rs m | 2,070 | 2,305 | 89.8% | |
| Net working cap to sales | % | 20.0 | 8.9 | 223.2% | |
| Current ratio | x | 1.6 | 1.1 | 135.5% | |
| Inventory Days | Days | 72 | 135 | 53.4% | |
| Debtors Days | Days | 35 | 46 | 75.4% | |
| Net fixed assets | Rs m | 790 | 4,871 | 16.2% | |
| Share capital | Rs m | 50 | 123 | 40.5% | |
| "Free" reserves | Rs m | 2,419 | 3,496 | 69.2% | |
| Net worth | Rs m | 2,469 | 3,619 | 68.2% | |
| Long term debt | Rs m | 0 | 1,374 | 0.0% | |
| Total assets | Rs m | 4,605 | 7,509 | 61.3% | |
| Interest coverage | x | NM | 0.2 | - | |
| Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
| Sales to assets ratio | x | 1.2 | 0.5 | 250.0% | |
| Return on assets | % | 5.6 | 0.6 | 891.2% | |
| Return on equity | % | 10.5 | -8.5 | -123.7% | |
| Return on capital | % | 17.7 | 1.6 | 1,121.2% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 13.9 | 0.0% | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | 517 | 0.0% | |
| Fx inflow | Rs m | 300 | 0 | - | |
| Fx outflow | Rs m | 2,015 | 517 | 390.1% | |
| Net fx | Rs m | -1,715 | -517 | 332.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 514 | 17.1% | |
| From Investments | Rs m | -94 | -123 | 76.0% | |
| From Financial Activity | Rs m | NA | -387 | 0.0% | |
| Net Cashflow | Rs m | -6 | 4 | -135.7% | |
Share Holding
| Indian Promoters | % | 0.0 | 32.9 | - | |
| Foreign collaborators | % | 75.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 0.3 | 0.2 | 166.7% | |
| FIIs | % | 15.7 | 0.6 | 2,706.9% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 66.4 | 13.7% | |
| Shareholders | 12,856 | 20,121 | 63.9% | ||
| Pledged promoter(s) holding | % | 0.0 | 36.4 | - |
Compare ASTRAZENECA PHARMA With: PIRAMAL ENTERPRISES NOVARTIS PANACEA BIOTECH DR. REDDYS LAB GSK PHARMA
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Opens in Green; TCS and Bharti Airtel Top Gainers(09:30 am)
Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.7% while the Hang Seng is up 1.1%.
Related Views on News
VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)
Jun 12, 2019 | Updated on Jun 12, 2019For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)
Jul 9, 2019As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)
Jul 8, 2019A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...
Here's What to Do with Falling Small Cap Stocks(Profit Hunter)
Jul 10, 2019There are some great buying opportunities in the market right now - and the small cap space is your best bet.
Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)
Jul 10, 2019Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.
More|
| |
ASTRAZENECA PHARMA SHARE PRICE
Jul 19, 2019 11:37 AM
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 8-QTR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.